CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 186 enrolled
Drug / intervention
Fibrin Sealant Grifols +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03461406
NCT03461406Phase 3Completed

A Prospective, Randomized, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Haemostasis During Surgery in Paediatric Subjects

Instituto Grifols, S.A.·interventional·Posted Mar 12, 2018·Updated Apr 14, 2023

In Brief

A Phase 3 clinical trial evaluating Fibrin Sealant Grifols and EVICEL for Excessive Bleeding During Surgery. Completed, enrolled 186 participants across 40 sites in 10 countries.

Detailed Summary

The objective of the study is to evaluate if FS Grifols is non-inferior to EVICEL® in terms of the percentage of participants achieving hemostasis at the target bleeding site (TBS) by 4 minutes (T4) from the start of treatment application (TStart) with no occurrence of rebleeding until the completion of the surgical closure by layers of the exposed surgical field containing the TBS (TClosure).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBulgaria, Canada, France, Germany, Hungary, Romania, Serbia, Sweden, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedMar 12, 2018
Enrollment StartJan 18, 2019
Primary CompletionApr 15, 2022
Study CompletionMay 20, 2022
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 8.3 years ago

Interventions

Fibrin Sealant Grifolsbiological

The FE Grifols solution was applied topically via drip or spray application.

EVICELbiological

The EVICEL solution was applied topically via drip or spray application.